Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Phase IIb Study of 610 in Participants With Severe Eosinophilic Asthma
Sponsor: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Summary
This study will assess the effcacy and safety of 610 as an adjunctive therapy in adult subjects with severe eosinophilic asthma.
Official title: A Multicenter, Randomized, Double-blind, Placebo-controlled Phase IIb, Effcacy and Safety Study of Recombinant Anti-IL-5 Humanized Monoclonal Antibody Therapy in Adult Subjects With Severe Asthma
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
225
Start Date
2024-12-20
Completion Date
2027-09
Last Updated
2026-01-29
Healthy Volunteers
No
Conditions
Interventions
610
Subcutaneously injection.
610
Subcutaneously injection.
Placebo
Subcutaneously injection.
Locations (1)
Shanghai General Hospital
Shanghai, Shanghai Municipality, China